333-008-1610 Medical Marijuana Processors: Definitions For purposes of OAR 333-008-1600 to 333-008-2200: (1) "Cannabinoid capsule" means a small soluble pill, tablet, or container that contains liquid or powdered cannabinoid product, concentrate or extract and is intended for human ingestion. (2) "Cannabinoid edible" means a food or potable liquid into which a cannabinoid concentrate or extract or the dried leaves or flowers of marijuana have been incorporated. (3) "Cannabinoid suppository" means a small soluble container designed to melt at body temperature within a body cavity other than the mouth, especially the rectum or vagina, containing a cannabinoid product, concentrate or extract. (4) "Cannabinoid tincture" means a liquid cannabinoid product packaged in a container of four fluid ounces or less that consists of either: (a) A non-potable solution of at least 25 percent non-denatured alcohol, in addition to cannabinoid concentrate, extract, or usable marijuana, and perhaps other ingredients intended for human consumption or ingestion that is exempt from the Liquor Control Act under ORS 471.035; or (b) A non-potable solution comprised of glycerin, plant-based oil, or concentrated syrup, cannabinoid concentrate, extract or usable marijuana; and perhaps other ingredients that does not contain any added sweeteners and is intended for human consumption or ingestion. (5) "Cannabinoid topical" means a cannabinoid product intended to be applied to skin or hair. (6) "Cannabinoid transdermal patch" means an adhesive substance applied to human skin that contains a cannabinoid product, concentrate or extract for absorption into the bloodstream. (7) "Food" means a raw, cooked, or processed edible substance, beverage or ingredient used or intended for use or for sale in whole or in part for human consumption, or chewing gum. (8) "Person responsible for the marijuana processing site" or "PRP" means an individual who is directly involved in the day-to-day operation of a processing site and is identified as a PRP on an application. (9) "Primary PRP" means a PRP designated by the owner of the processing site as the primary point of contact for the Oregon Health Authority (Authority) and who is authorized to receive any and all communications and legal notices from the Authority. (10) "Processing site representative" means an owner, director, officer, PRP, manager, employee, agent or other representative of a registered processing site, to the extent that the person acts in a representative capacity. (11) "Processing site registrant” means: (a) An individual who owns a registered processing site or if a business entity owns the registered processing site, each individual who has a financial interest in the registered processing site; and (b) Any PRP. (12) "These rules" means OAR 333-008-1600 to 333-008-2200 and 333-008-5000. Statutory/Other Authority: ORS 475C.815 Statutes/Other Implemented: ORS 475C.815 History: PH 27-2025, amend filed 12/30/2025, effective 01/01/2026 PH 115-2022, minor correction filed 06/07/2022, effective 06/07/2022 PH 282-2018, amend filed 12/20/2018, effective 01/01/2019 PH 212-2018, minor correction filed 05/17/2018, effective 05/17/2018 PH 162-2018, minor correction filed 04/30/2018, effective 04/30/2018 PH 21-2016, f. 6-24-16, cert. ef. 6-28-16 PH 9-2016, f. 2-26-16, cert. ef. 3-1-16